Regencell Bioscience (NASDAQ:RGC) Trading Down 4.2% – Here’s Why

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s share price fell 4.2% during mid-day trading on Monday . The company traded as low as $11.78 and last traded at $11.96. 95,263 shares were traded during trading, a decline of 99% from the average session volume of 7,994,849 shares. The stock had previously closed at $12.48.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, November 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Regencell Bioscience Price Performance

The firm’s fifty day moving average is $15.43.

Hedge Funds Weigh In On Regencell Bioscience

A number of hedge funds have recently added to or reduced their stakes in RGC. Greenfield Savings Bank purchased a new position in Regencell Bioscience during the 2nd quarter worth $187,000. Y Intercept Hong Kong Ltd bought a new position in shares of Regencell Bioscience during the 2nd quarter worth approximately $222,000. XTX Topco Ltd purchased a new position in shares of Regencell Bioscience in the 3rd quarter worth approximately $598,000. BNP Paribas Financial Markets bought a new position in shares of Regencell Bioscience in the second quarter valued at approximately $768,000. Finally, Squarepoint Ops LLC bought a new position in shares of Regencell Bioscience in the second quarter valued at approximately $1,701,000. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.